The global sleep apnea diagnostics market was valued at $290.50 million in 2020, and is projected to reach $545.09 million by 2030, registering a CAGR of 6.7% from 2021 to 2030.
Obstructive sleep-disordered breathing (SDB) is a syndrome of upper airway dysfunction during sleep that is characterized by snoring and/or increased respiratory effort secondary to greater upper airway resistance and pharyngeal collapsibility. Obstructive sleep apnea (OSA) is a sleep disorder that results in significant decrease or cessation of airflow in the presence of breathing effort. If the brain does not send the signals needed to breathe, the condition is referred to as central sleep apnea. Around 85–90% of OSA patients are estimated to remain undiagnosed that demonstrates the unmet medical needs. Sleep apnea diagnostic products evaluate the breathing and other body functions of patients during sleep, thereby boosting the demand for these devices to combat sleep apnea disease. The general characteristic of Obstructive Sleep Apnea is the increased collapsibility of the upper airway during sleep resulting in markedly reduced (hypopnea) or absent (apnea) airflow at the nose and/or mouth which is usually accompanied by oxyhemoglobin desaturation and is typically terminated by a brief micro-arousal. Repeated episodes of apnea lead to a sustained reduction in oxyhemoglobin saturation and sleep fragmentation with diminished amounts of slow-wave and rapid eye movement (REM) sleep. The major predisposing factor for sleep apnea is excess body weight. It has been estimated that 58% of moderate to severe OSA is attributable to obesity.
The global sleep apnea diagnostic market is anticipated to register notable growth due to increase in geriatric population as well as a surge in prevalence of sedentary lifestyle disorders such as obesity and diabetes, as well as considerable increase in awareness about sleep apnea. Furthermore, technical developments to make products more convenient for users as well as a notable increase in sleep apnea diseases are driving market expansion. However, the market is expected to be hampered by the high cost of sleep apnea treatment tools, restricted reimbursement for these devices, and low patient compliance. On the contrary, the progressive rise in popularity of home healthcare equipment is expected to provide attractive development opportunities for the global market in the near future.
The global sleep apnea diagnostics market is segmented into product, end user, and region. Depending on product, the market is fragmented into polysomnography (PSG) devices, actigraphy systems, respiratory polygraph, sleep apnea screening device, oximeter, and others. On the basis of end user, it is bifurcated into sleep laboratory & hospital and home healthcare. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans. supply chains were disrupted due to restrictions on trade of pharmaceutical ingredients and products across countries. The outbreak of COVID-19 has disrupted workflows in the healthcare sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare. In the initial days of the COVID-19 pandemic 2020, some countries were in lockdown. They banned trade with other nations and enforced travel restrictions, resulting in decline in diagnostics and surgical procedures in the first half of 2020. In addition, COVID 19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. In its disruption to clinical trials and drug supply to patients, the COVID-19 pandemic has impacted the most crucial areas of the sleep apnea diagnostics market. The banned trade with other nations and enforced travel restrictions, resulting in decline in diagnostics and surgical procedures in the first half of 2020. According to the study published in the British Journal of Surgery, around 28.4 million elective procedures were cancelled or postponed in May 2020, based on a 12-week period of peak disruption to hospital services due to COVID-19. There has been a significant reduction in hospitals and sleep laboratory-based diagnosis of sleep apnea. Overall impact of the COVID-19 pandemic on the global sleep apnea market was recorded to be negative, owing to the factors such as sleep lab were closed due to lockdown in many countries. However, this situation is expected to change post COVID-19 pandemic in the coming years.
Obstructive sleep-disordered breathing (SDB) is a syndrome of upper airway dysfunction during sleep that is characterized by snoring and/or increased respiratory effort secondary to greater upper airway resistance and pharyngeal collapsibility. Obstructive sleep apnea (OSA) is a sleep disorder that results in significant decrease or cessation of airflow in the presence of breathing effort. If the brain does not send the signals needed to breathe, the condition is referred to as central sleep apnea. Around 85–90% of OSA patients are estimated to remain undiagnosed that demonstrates the unmet medical needs. Sleep apnea diagnostic products evaluate the breathing and other body functions of patients during sleep, thereby boosting the demand for these devices to combat sleep apnea disease. The general characteristic of Obstructive Sleep Apnea is the increased collapsibility of the upper airway during sleep resulting in markedly reduced (hypopnea) or absent (apnea) airflow at the nose and/or mouth which is usually accompanied by oxyhemoglobin desaturation and is typically terminated by a brief micro-arousal. Repeated episodes of apnea lead to a sustained reduction in oxyhemoglobin saturation and sleep fragmentation with diminished amounts of slow-wave and rapid eye movement (REM) sleep. The major predisposing factor for sleep apnea is excess body weight. It has been estimated that 58% of moderate to severe OSA is attributable to obesity.
The global sleep apnea diagnostic market is anticipated to register notable growth due to increase in geriatric population as well as a surge in prevalence of sedentary lifestyle disorders such as obesity and diabetes, as well as considerable increase in awareness about sleep apnea. Furthermore, technical developments to make products more convenient for users as well as a notable increase in sleep apnea diseases are driving market expansion. However, the market is expected to be hampered by the high cost of sleep apnea treatment tools, restricted reimbursement for these devices, and low patient compliance. On the contrary, the progressive rise in popularity of home healthcare equipment is expected to provide attractive development opportunities for the global market in the near future.
The global sleep apnea diagnostics market is segmented into product, end user, and region. Depending on product, the market is fragmented into polysomnography (PSG) devices, actigraphy systems, respiratory polygraph, sleep apnea screening device, oximeter, and others. On the basis of end user, it is bifurcated into sleep laboratory & hospital and home healthcare. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans. supply chains were disrupted due to restrictions on trade of pharmaceutical ingredients and products across countries. The outbreak of COVID-19 has disrupted workflows in the healthcare sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare. In the initial days of the COVID-19 pandemic 2020, some countries were in lockdown. They banned trade with other nations and enforced travel restrictions, resulting in decline in diagnostics and surgical procedures in the first half of 2020. In addition, COVID 19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. In its disruption to clinical trials and drug supply to patients, the COVID-19 pandemic has impacted the most crucial areas of the sleep apnea diagnostics market. The banned trade with other nations and enforced travel restrictions, resulting in decline in diagnostics and surgical procedures in the first half of 2020. According to the study published in the British Journal of Surgery, around 28.4 million elective procedures were cancelled or postponed in May 2020, based on a 12-week period of peak disruption to hospital services due to COVID-19. There has been a significant reduction in hospitals and sleep laboratory-based diagnosis of sleep apnea. Overall impact of the COVID-19 pandemic on the global sleep apnea market was recorded to be negative, owing to the factors such as sleep lab were closed due to lockdown in many countries. However, this situation is expected to change post COVID-19 pandemic in the coming years.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
- An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the sleep apnea diagnostics market is provided.
- An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
KEY MARKET SEGMENTS
By PRODUCT
- Polysomnography device (PSG)
- Clinical PSG device
- Ambulatory PSG device
- Sleep apnea screening device
- Actigraphy monitoring device
- Respiratory polygraph
- Oximeter
- Fingertip oximeter
- Handheld oximeter
- Wrist-worn oximeter
- Tabletop oximeter
By END USER
- Hospitals & sleep laboratories
- Homecare settings
By REGION
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
KEY MARKET PLAYERS
- Cadwell Industries Inc.
- DeVilbiss Healthcare LLC
- Koninklijke Philips N.V.
- Medtronic PLC.
- Mindray Medical International Limited
- Natus Medical Incorporated
- Nihon Kohden Corporation
- Resmed Inc.
- Smiths Group Plc. (Smiths Medical)
- SomnoMedics GmbH
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: SLEEP APNEA DIAGNOSTICS MARKET, BY PRODUCT
CHAPTER 5: SLEEP APNEA DIAGNOSTICS MARKET, BY END USER
CHAPTER 6: SLEEP APNEA DIAGNOSTICS MARKET, BY REGION
CHAPTER 7: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- CADWELL INDUSTRIES INC
- DEVILBISS HEALTHCARE
- KONINKLIJKE PHILIPS N.V. (PHILIPS)
- MEDTRONIC PLC
- MINDRAY MEDICAL INTERNATIONAL LIMITED
- NATUS MEDICAL INCORPORATED
- NIHON KOHDEN CORPORATION
- RESMED IN
- SMITHS GROUP PLC. (SMITHS MEDICAL)
- SOMNOMEDICS Gmb
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 207 |
| Published | November 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 290.5 million |
| Forecasted Market Value ( USD | $ 545.09 million |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
